Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
Overall survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).
1 finding from 1 review
Long‐term mortality · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
Mortality before hospital discharge · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
It is very uncertain whether inhaled nitric oxide changes mortality prior to discharge1 compared with placebo or conventional therapy (very low certainty).
1 finding from 1 review
Difference in MPAP change score (SE) ‐ Conventional Management4 · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review